Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

Key Findings:  The evidence available to-date has demonstrated a potentially significant role of cannabinoids in the treatment of dementia for neurodegenerative disorders including: Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD) and vascular dementia (VD).

Type of Study:  Meta-analysis

Study Result:  Positive

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), CP-x Synthetic Cannabinoids, AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Synthetic Cannabinoid (unspecified), Pharma THC

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype III, Chemotype I

Form of Administration:  Not Applicable

Receptors Studied:  CB1, CB2

Ligands Studied:  Acetylcholine, GABA, Glutamate, Pro-inflammatory cytokines

Study Location(s):  Switzerland

Year of Pub:  2019

Link to study